These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 9852888)

  • 1. Anticoagulation is unnecessary after biological aortic valve replacement.
    Moinuddeen K; Quin J; Shaw R; Dewar M; Tellides G; Kopf G; Elefteriades J
    Circulation; 1998 Nov; 98(19 Suppl):II95-8; discussion II98-9. PubMed ID: 9852888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors.
    Brueck M; Kramer W; Vogt P; Steinert N; Roth P; Görlach G; Schönburg M; Heidt MC
    Eur J Cardiothorac Surg; 2007 Jul; 32(1):108-12. PubMed ID: 17449264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?
    Sundt TM; Zehr KJ; Dearani JA; Daly RC; Mullany CJ; McGregor CG; Puga FJ; Orszulak TA; Schaff HV
    J Thorac Cardiovasc Surg; 2005 May; 129(5):1024-31. PubMed ID: 15867776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm?
    ElBardissi AW; DiBardino DJ; Chen FY; Yamashita MH; Cohn LH
    J Thorac Cardiovasc Surg; 2010 May; 139(5):1137-45. PubMed ID: 20303508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial.
    Colli A; Mestres CA; Castella M; Gherli T
    J Heart Valve Dis; 2007 Nov; 16(6):667-71. PubMed ID: 18095518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mid-term pattern of survival, hemodynamic performance and rate of complications after medtronic freestyle versus homograft full aortic root replacement: results from a prospective randomized trial.
    Melina G; De Robertis F; Gaer JA; Amrani M; Khaghani A; Yacoub MH
    J Heart Valve Dis; 2004 Nov; 13(6):972-5; discussion 975-6. PubMed ID: 15597592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-do aortic valve replacement: does a previous homograft influence the operative outcome?
    Kumar P; Athanasiou T; Ali A; Nair S; Oz BS; DeSouza A; Moat N; Shore DF; Pepper JR
    J Heart Valve Dis; 2004 Nov; 13(6):904-12; discussion 912-3. PubMed ID: 15597580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose oral anticoagulation and antiplatelet therapy with St. Jude Medical heart valve prosthesis.
    Yamak B; Iscan Z; Mavitas B; Ulus AT; Katircioglu SF; Tasdemir O; Bayazit K
    J Heart Valve Dis; 1999 Nov; 8(6):665-73. PubMed ID: 10616246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early postoperative anticoagulation after mechanical valve replacement: a Canadian survey.
    Kulik A; Rubens FD; Baird D; Wells PS; Kearon C; Mesana TG; Lam BK
    J Heart Valve Dis; 2006 Jul; 15(4):581-7. PubMed ID: 16901058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mid-term results after Epic xenograft implantation for aortic, mitral, and double valve replacement.
    Lehmann S; Walther T; Leontjev S; Kempfert J; Rastan A; Garbade J; Borger MA; Falk V; Mohr FW
    J Heart Valve Dis; 2007 Nov; 16(6):641-8; discussion 648. PubMed ID: 18095514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aortic valve replacement: a prospective randomized evaluation of mechanical versus biological valves in patients ages 55 to 70 years.
    Stassano P; Di Tommaso L; Monaco M; Iorio F; Pepino P; Spampinato N; Vosa C
    J Am Coll Cardiol; 2009 Nov; 54(20):1862-8. PubMed ID: 19892237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eighteen-year follow up after Hancock II bioprosthesis insertion.
    Legarra JJ; Llorens R; Catalan M; Segura I; Trenor AM; de Buruaga JS; Rabago G; Sarralde A
    J Heart Valve Dis; 1999 Jan; 8(1):16-24. PubMed ID: 10096477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioprosthetic versus mechanical prostheses for aortic valve replacement in the elderly.
    Davis EA; Greene PS; Cameron DE; Gott VI; Laschinger JC; Stuart RS; Sussman MS; Watkins L; Baumgartner WA
    Circulation; 1996 Nov; 94(9 Suppl):II121-5. PubMed ID: 8901731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical management of aortic valve disease in the elderly: A retrospective comparative study of valve choice using propensity score analysis.
    Accola KD; Scott ML; Palmer GJ; Thompson PA; Sand ME; Suarez-Cavalier JE; Bott JN; Ebra G
    J Heart Valve Dis; 2008 Jul; 17(4):355-64; discussion 365. PubMed ID: 18751463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP).
    Pengo V; Palareti G; Cucchini U; Molinatti M; Del Bono R; Baudo F; Ghirarduzzi A; Pegoraro C; Iliceto S;
    Clin Appl Thromb Hemost; 2007 Jul; 13(3):241-8. PubMed ID: 17636186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy.
    Slaughter MS; Naka Y; John R; Boyle A; Conte JV; Russell SD; Aaronson KD; Sundareswaran KS; Farrar DJ; Pagani FD
    J Heart Lung Transplant; 2010 Jun; 29(6):616-24. PubMed ID: 20400335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of anticoagulation regimens after Carpentier-Edwards aortic or mitral valve replacement.
    Blair KL; Hatton AC; White WD; Smith LR; Lowe JE; Wolfe WG; Young WG; Oldham HN; Douglas JM; Glower DD
    Circulation; 1994 Nov; 90(5 Pt 2):II214-9. PubMed ID: 7955256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seventeen-year experience with the St. Jude medical biocor porcine bioprosthesis.
    Mykén PS
    J Heart Valve Dis; 2005 Jul; 14(4):486-92. PubMed ID: 16116875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjusting anticoagulation to prosthesis thrombogenicity and patient risk factors. Recommendations for the Medtronic Hall valve.
    Butchart EG; Lewis PA; Bethel JA; Breckenridge IM
    Circulation; 1991 Nov; 84(5 Suppl):III61-9. PubMed ID: 1934443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.